Advagene Biopharma Co., Ltd. (6709) Stock Statistics & Valuation Metrics
Total Valuation
Advagene Biopharma Co., Ltd. has a market cap or net worth of TWD 1.44B. The enterprise value is ―.
- Market Cap
- TWD 1.44B
- Enterprise Value
- ―
Share Statistics
Advagene Biopharma Co., Ltd. has 69,380,000 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 69,380,000
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Advagene Biopharma Co., Ltd.’s return on equity (ROE) is -0.45 and return on invested capital (ROIC) is -45.40%.
- Return on Equity (ROE)
- -0.45
- Return on Assets (ROA)
- -0.41
- Return on Invested Capital (ROIC)
- -45.40%
- Return on Capital Employed (ROCE)
- -0.46
- Revenue Per Employee
- 0
- Profits Per Employee
- -4.27M
- Employee Count
- 16
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Advagene Biopharma Co., Ltd. is -14.30. Advagene Biopharma Co., Ltd.’s PEG ratio is 0.54.
- PE Ratio
- -14.30
- PS Ratio
- 0.00
- PB Ratio
- 3.68
- Price to FCF
- -16.55
- Price to Operating Cash Flow
- -14.93
- PEG Ratio
- 0.54
Income Statement
In the last 12 months, Advagene Biopharma Co., Ltd. had revenue of 0 and earned -68.29M in profits. Earnings per share was -1.15.
- Revenue
- 0
- Gross Profit
- -2.19M
- Operating Income
- -70.92M
- Pretax Income
- -68.29M
- Net Income
- -68.29M
- EBITDA
- -68.73M
- Earnings Per Share (EPS)
- -1.15
Cash Flow
In the last 12 months, operating cash flow was -87.86M and capital expenditures -2.71M, giving a free cash flow of -90.56M billion.
- Operating Cash Flow
- -87.86M
- Free Cash Flow
- -90.56M
- Free Cash Flow per Share
- -1.49
Dividends & Yields
Advagene Biopharma Co., Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -6.04%
- Earnings Yield
- -6.94%
Stock Price Statistics
- Beta
- 0.65
- 52-Week Price Change
- -36.76%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 31.22
- Average Volume (3m)
- 50.47K
Financial Position
Advagene Biopharma Co., Ltd. as a current ratio of 13.69, with Debt / Equity ratio of 2.61%
- Current Ratio
- 13.69
- Quick Ratio
- 13.69
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.75
- Interest Coverage Ratio
- -405.25
Taxes
In the past 12 months, Advagene Biopharma Co., Ltd. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Advagene Biopharma Co., Ltd. EV to EBITDA ratio is -13.99, with an EV/FCF ratio of -13.66.
- EV to Sales
- 0.00
- EV to EBITDA
- -13.99
- EV to Free Cash Flow
- -13.66
- EV to Operating Cash Flow
- -14.08
Balance Sheet
Advagene Biopharma Co., Ltd. has TWD 325.18M in cash and marketable securities with TWD 3.73M in debt, giving a net cash position of TWD 321.45M billion.
- Cash & Marketable Securities
- TWD 325.18M
- Total Debt
- TWD 3.73M
- Net Cash
- TWD 321.45M
- Net Cash Per Share
- TWD 4.63
- Tangible Book Value Per Share
- TWD 5.74
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Advagene Biopharma Co., Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -22.43%
